SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oncolytics Biotech Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: grayhairs who wrote (21)10/17/2000 7:50:13 AM
From: Gulo  Read Replies (1) of 103
 
You're not dreaming.

The main limitation I see is that many people have a natural immunity to the virus (prior exposure). As an adjunct to mild chemotherapy, the virus has great potential.
In a best case scenario, all that would be required is to suppress the immune system a bit so that the virus can propagate and reach mestastases.

I would really like to know how the toxicity (Phase I) study is going.

-g
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News